ANIX is trading at $3.11 (+5.06%) today after treating the first patient in the highest-dose fifth cohort of its Phase 1 ovarian cancer CAR-T trial.
- No dose-limiting toxicities were reported in the latest cohort, supporting investor confidence in the program's safety profile.
- The stock is significantly outperforming broader markets on this company-specific biotech catalyst.
- Pre-market quotes reached $3.1167 (+5.29%), reinforcing the strength behind the move.